Clinical stage opportunities AffyImmune is a clinical-stage biotech focusing on optimizing CAR T cells for solid tumors with AIC100 targeting thyroid cancer and potentially other cancers. This presents a sales angle to CDMO partners, clinical trial management vendors, and regulatory consultants involved in early-stage oncology programs.

Small team agility With a lean headcount of 2-10 employees, AffyImmune may seek scalable collaboration, outsourcing, and external software or service providers to support research, data analysis, regulatory filings, and non-core activities, creating cross-sell opportunities for CROs, data analytics vendors, and cloud-based collaboration tools.

Board & leadership moves Recent appointments to the board and executive leadership (CFO/CEO transitions and new Chief Medical Officer) signal active strategic development and governance changes, implying a window for engagement with strategic advisors, investor relations consultants, and interim leadership services.

Data and tech stack The use of tools like Power BI, Tableau, GraphPad Prism, and collaboration platforms suggests openness to data visualization, statistical analysis, and regulatory documentation support services, enabling opportunities with analytics firms, CROs, and IT consultants.

Funding and proximity to commercialization With funding of $29M and revenue under $1M, AffyImmune is likely prioritizing partnerships for manufacturing, clinical development, and regulatory approval support to accelerate the AIC100 program, presenting opportunities with CMOs, contract manufacturers, and regulatory consultancies.